$VANI
Vivani Medical, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020040021 Filed on August 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $497.0K $1.282M
YoY Change -71.87% -32.77%
Cost Of Revenue $0.00 $120.0K $933.0K
YoY Change -100.0% -92.5% 11.6%
Gross Profit $373.0K $349.0K
YoY Change 123.35% -67.41%
Gross Profit Margin 75.05% 27.22%
Selling, General & Admin $1.950M $4.290M $3.945M
YoY Change -50.57% -29.09% -28.42%
% of Gross Profit 1150.13% 1130.37%
Research & Development $320.0K $4.150M $3.436M
YoY Change -90.69% 70.08% 41.87%
% of Gross Profit 1112.6% 984.53%
Depreciation & Amortization $20.00K $110.0K $100.0K
YoY Change -80.0% 0.0% -9.09%
% of Gross Profit 29.49% 28.65%
Operating Expenses $2.270M $8.440M $8.790M
YoY Change -74.18% -0.47% -2.97%
Operating Profit -$3.116M -$8.126M -$8.441M
YoY Change -63.08% -8.46% 5.67%
Interest Expense $20.00K $260.0K $0.00
YoY Change 1200.0% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.100M -$7.870M -$8.440M
YoY Change -63.27% -11.17% 6.03%
Income Tax
% Of Pretax Income
Net Earnings -$3.100M -$7.868M -$8.440M
YoY Change -63.27% -11.18% 6.02%
Net Earnings / Revenue -1583.1% -658.35%
Basic Earnings Per Share
Diluted Earnings Per Share -$152.4K -$504.2K -$543.1K
COMMON SHARES
Basic Shares Outstanding 124.6M 124.2M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.510M $11.33M $25.16M
YoY Change -86.05% 153.47% 236.36%
Cash & Equivalents $3.505M $11.33M $25.16M
Short-Term Investments
Other Short-Term Assets $1.080M $300.0K $780.0K
YoY Change 38.46% -78.57% 30.0%
Inventory $0.00 $1.029M $1.474M
Prepaid Expenses
Receivables $0.00 $455.0K $629.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.581M $13.11M $28.05M
YoY Change -83.67% 36.28% 126.92%
LONG-TERM ASSETS
Property, Plant & Equipment $212.0K $1.122M $993.0K
YoY Change -78.65% 9.46% -16.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.00K $30.00K $30.00K
YoY Change -66.67% -25.0% -57.14%
Other Assets
YoY Change
Total Long-Term Assets $224.0K $3.489M $3.473M
YoY Change -93.55% 228.53% 176.29%
TOTAL ASSETS
Total Short-Term Assets $4.581M $13.11M $28.05M
Total Long-Term Assets $224.0K $3.489M $3.473M
Total Assets $4.805M $16.60M $31.52M
YoY Change -84.76% 55.39% 131.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $517.0K $1.093M $1.255M
YoY Change -58.8% -16.25% 2.87%
Accrued Expenses $1.023M $1.889M $2.562M
YoY Change -60.07% -24.53% 23.71%
Deferred Revenue $335.0K $335.0K $557.0K
YoY Change -39.86% 100.6% 114.23%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.722M $6.959M $7.838M
YoY Change -65.27% -8.41% 10.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $2.370M $2.490M
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $2.370M $2.490M
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.722M $6.959M $7.838M
Total Long-Term Liabilities $0.00 $2.370M $2.490M
Total Liabilities $2.722M $9.324M $10.33M
YoY Change -73.64% 22.72% 46.04%
SHAREHOLDERS EQUITY
Retained Earnings -$316.8M -$304.8M -$289.3M
YoY Change 9.48% 13.1% 14.77%
Common Stock $270.1M $264.0M $263.7M
YoY Change 2.45% 15.28% 21.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.083M $7.725M $21.20M
YoY Change
Total Liabilities & Shareholders Equity $4.805M $16.60M $31.52M
YoY Change -84.76% 55.39% 131.48%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income -$3.100M -$7.868M -$8.440M
YoY Change -63.27% -11.18% 6.02%
Depreciation, Depletion And Amortization $20.00K $110.0K $100.0K
YoY Change -80.0% 0.0% -9.09%
Cash From Operating Activities -$5.240M -$7.390M -$6.640M
YoY Change -21.08% -4.4% -15.31%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$100.0K -$120.0K
YoY Change -100.0% 400.0% 140.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$100.0K -$120.0K
YoY Change -100.0% 400.0% 140.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.410M 350.0K 240.0K
YoY Change 2570.83% -95.17% -97.69%
NET CHANGE
Cash From Operating Activities -5.240M -7.390M -6.640M
Cash From Investing Activities 0.000 -100.0K -120.0K
Cash From Financing Activities 6.410M 350.0K 240.0K
Net Change In Cash 1.170M -7.140M -6.520M
YoY Change -117.94% 1300.0% -361.85%
FREE CASH FLOW
Cash From Operating Activities -$5.240M -$7.390M -$6.640M
Capital Expenditures $0.00 -$100.0K -$120.0K
Free Cash Flow -$5.240M -$7.290M -$6.520M
YoY Change -19.63% -5.45% -16.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49260000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-533000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316770000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
2083000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4805000
CY2020Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
335000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2722000
CY2020Q2 us-gaap Liabilities
Liabilities
2722000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
CY2020Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23118000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23118000
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1282000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CA
dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3505000
dei Document Type
DocumentType
10-Q
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2365000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
270126000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1664000
us-gaap Gross Profit
GrossProfit
746000
us-gaap Restructuring Charges
RestructuringCharges
2229000
us-gaap Restructuring Charges
RestructuringCharges
3297000
us-gaap Operating Expenses
OperatingExpenses
12020000
us-gaap Operating Expenses
OperatingExpenses
18955000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12020000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18209000
us-gaap Interest Income Operating
InterestIncomeOperating
34000
us-gaap Interest Income Operating
InterestIncomeOperating
69000
us-gaap Net Income Loss
NetIncomeLoss
-11986000
us-gaap Net Income Loss
NetIncomeLoss
-18140000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.28
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17993000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13816000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
29000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
455000
CY2020Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
400000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
299000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2342000
CY2020Q2 eyes Deposits And Other Assets
DepositsAndOtherAssets
12000
CY2020Q2 us-gaap Assets
Assets
4805000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
517000
CY2019Q4 us-gaap Inventory Net
InventoryNet
1029000
CY2019Q4 us-gaap Assets
Assets
16599000
CY2019Q4 eyes Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
707000
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1122000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
13110000
dei Entity File Number
EntityFileNumber
001-36747
CY2019Q4 eyes Deposits And Other Assets
DepositsAndOtherAssets
25000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
330000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1093000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
676000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
4581000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
212000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1023000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1889000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2698000
CY2020Q2 eyes Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
517000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
237000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
335000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6959000
CY2019Q4 us-gaap Liabilities
Liabilities
9324000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11957000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18139000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-304784000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7275000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16599000
CY2019Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15643000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15643000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
264008000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48613000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-562000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2410000
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
933000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5619000
CY2018Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-144000
CY2019Q1 eyes Stock Issued During Period Value Common Stock And Warrants In Connection With Rights Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts
34399000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
898000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-9700000
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-8000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
28529000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
238000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
859000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
21195000
CY2020Q1 eyes Repurchase Of Fractional Shares In Connection With Reverse Stock Split
RepurchaseOfFractionalSharesInConnectionWithReverseStockSplit
11000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
279000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8886000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
19000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1318000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
126000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
196000
us-gaap Share Based Compensation
ShareBasedCompensation
367000
us-gaap Share Based Compensation
ShareBasedCompensation
1757000
us-gaap Operating Lease Expense
OperatingLeaseExpense
3000
us-gaap Operating Lease Expense
OperatingLeaseExpense
10000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1115000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
2587000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-461000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
122000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
144000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
364000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
364000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-585000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1019000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-49000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
108000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
192000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2369000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-483000
eyes Increase Decrease Accrued Clinical Trial Expenses
IncreaseDecreaseAccruedClinicalTrialExpenses
-189000
eyes Increase Decrease Accrued Clinical Trial Expenses
IncreaseDecreaseAccruedClinicalTrialExpenses
105000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
387000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13891000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13785000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
331000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-331000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-164000
eyes Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
6679000
eyes Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
34399000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
238000
eyes Repurchase Of Espp Shares And Fractional Shares In Connection With Reverse Stock Split
RepurchaseOfESPPSharesAndFractionalSharesInConnectionWithReverseStockSplit
281000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6398000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34637000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
2000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7822000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20690000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4471000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25161000
eyes Fair Value Of Warrants Issued In Connection With Issuance Of Common Stock
FairValueOfWarrantsIssuedInConnectionWithIssuanceOfCommonStock
280000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Business Operations</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Sight Medical Products, Inc. (&#8220;Second Sight,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;the Company&#8221;) was incorporated in the State of California in 2003. Second Sight develops implantable visual prosthetics to potentially enable blind individuals to achieve greater independence.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2007, Second Sight formed Second Sight Medical Products (Switzerland) S&#224;rl, initially to manage clinical trials and sales and marketing in Europe, the Middle East and Asia-Pacific, and more recently for the research of future technologies. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) S&#224;rl is 99.5% owned directly by us and 0.5% owned by an executive of Second Sight&#160;as of June 30, 2020. Accordingly, Second Sight Medical Products (Switzerland) S&#224;rl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented. In June 2020, we commenced a process to dissolve our Swiss subsidiary which is expected to take approximately one year.&#160;</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently developing the Orion<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Visual Cortical Prosthesis System (&#8220;Orion&#8221;), an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes including retinitis pigmentosa (RP), glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. The FDA granted Breakthrough Devices Program designation for Orion. A feasibility study of the Orion&#160;device is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles (&#8220;UCLA&#8221;) and Baylor College of Medicine in Houston (&#8220;Baylor&#8221;).</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our first commercially approved product, the Argus<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> II retinal prosthesis system (&#8220;Argus II&#8221;), entered clinical trials in 2006, received CE Mark approval for marketing and sales in the European Union (&#8220;EU&#8221;) in 2011, and received approval by the United States Food and Drug Administration (&#8220;FDA&#8221;) for marketing and sales in the United States in 2013. We began selling the Argus II in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, Turkey in 2015, Iran, Taiwan, South Korea and Russia in 2017, and Singapore in 2018. Given the limited addressable market of Argus II, we no longer market the Argus II and have focused all of our resources on the development of Orion.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we were severely adversely impacted by the COVID-19 pandemic and its related effects on our ability to finance our planned activities. As a result, we significantly reduced our staff and expenses and conserved liquidity as we continue operations and explore strategic options. These options include securing additional funding and exploring business alternatives that may include partnering, acquiring, investing in or combining with businesses that may or may not be in a related industry. No assurances can be given that any of these initiatives will occur.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. Funding of our business since 2017 has been primarily provided by:</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of shares of common stock on May 5, 2020 which provided net proceeds of approximately $6.7 million.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock and warrants in a Rights Offering in February 2019 which provided $34.4 million of net cash proceeds</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock through our At Market Issuance Sales Agreement during the fourth quarter of 2019 which provided $0.1 million of net cash proceeds</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock through our At Market Issuance Sales Agreement during the first quarter of 2018, which provided $4.0 million of net cash proceeds</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock via stock purchase agreements in May, August, October and December 2018, which provided net cash proceeds of $22.0 million</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue of $3.4 million and $6.9 million, for the years ended December 31, 2019 and 2018, respectively, generated by sales of our Argus II product</p></td></tr></table></div> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2020, we closed our underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate net proceeds of approximately $6.7 million.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received an award for $1.6 million grant (with the intent to fund $6.4 million over five years subject to annual review and approval) from the National Institutes of Health (NIH) to fund the &#8220;Early Feasibility Clinical Trial of a Visual Cortical Prosthesis&#8221; that commenced in January 2018. Our second year grant was recently approved under this grant. As of June 30, 2020 we recorded $0.3 million of deferred grant costs which will be offset with the related grant funds when received. During the six months ended June 30, 2020, we received a total of $0.4 million of grant funds primarily from this grant.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 17, 2019, we received a $2.4 million, four-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (&#8220;SLAM&#8221;). This grant involves a joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), and is intended to speed the integration of SLAM into future generations of Orion. The goal is to give Orion users the ability to localize objects and navigate landmarks in unfamiliar surroundings in real time. APL is the primary recipient of the grant. We have suspended our activities on the project until we clarify our future plans.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a rights offering completed on February 22, 2019, we sold approximately 5,976,000 million units, each priced at $5.792 for net proceeds of approximately $34.4 million. Each unit consisted of one share and one immediately exercisable warrant having an exercise price of $11.76 per share. Entities controlled by Gregg Williams, our Chairman of the Board of Directors, acquired approximately 5,180,000 million units in the offering for an aggregate investment of approximately $30 million.<font style="font-weight:bold;"> </font></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, we entered into an At Market Issuance Sales Agreement (&#8220;Sales Agreement&#8221;) with B. Riley FBR Inc. and H.C. Wainwright &amp; Co., LLC, as agents (&#8220;Agents&#8221;) pursuant to which we offered and sold, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold approximately 278,000 shares of common stock which provided net proceeds of $4.0 million under the Sales Agreement.<font style="font-size:12pt;">&#160;</font>During December 2019, we sold approximately 17,000 shares of common stock which provided net proceeds of $0.1 million under the Sales Agreement. In April 2020, we terminated the Sales Agreement with the Agents.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with no revenue that is developing a novel medical device, including limitations on our operating capital resources. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future.<font style="font-size:12pt;">&#160;&#160;</font></p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As more fully described in Note 11, we have been notified by the Nasdaq stock market regarding our non-compliance with the continued listing requirement on the Nasdaq capital market pursuant to its listing rules, and therefore we could be subject to delisting if we do not regain compliance within the compliance period (or the compliance period as may be extended).</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current plans we do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. Accordingly, these and other related factors raise substantial doubt about our ability to continue as a going concern. We anticipate that we will seek to additionally fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or any other approved product candidates, or we may be unable to maintain our current limited operations, maintain our current organization and reduced employee base or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, financial condition and results of operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</p> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our independent registered public accounting firm, in its report on our 2019 consolidated financial statements, has raised substantial doubt about our ability to continue as a going concern. </p>
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3400000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6900000
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q2 us-gaap Deferred Costs Current And Noncurrent
DeferredCostsCurrentAndNoncurrent
300000
CY2019Q3 eyes Grant Received To Develop Spatial Localization And Mapping Technology
GrantReceivedToDevelopSpatialLocalizationAndMappingTechnology
2400000
CY2019Q3 eyes Grant Received Funding Period
GrantReceivedFundingPeriod
P4Y
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8
CY2020Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
741000
CY2019Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
803000
CY2020Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1461000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1716000
CY2020Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1290000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2069000
CY2020Q2 us-gaap Inventory Gross
InventoryGross
3492000
CY2019Q4 us-gaap Inventory Gross
InventoryGross
4588000
CY2020Q2 us-gaap Inventory Adjustments
InventoryAdjustments
3492000
CY2019Q4 us-gaap Inventory Adjustments
InventoryAdjustments
3559000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
653000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4778000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
441000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3656000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1575000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
419000
eyes Product Warranty Accrual Total
ProductWarrantyAccrualTotal
1156000
eyes Finished Goods Inventory Expected To Be Used Or Future Warranty Claims
FinishedGoodsInventoryExpectedToBeUsedOrFutureWarrantyClaims
-399000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
757000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
117000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
117000
us-gaap Subordinated Borrowing Interest Rate
SubordinatedBorrowingInterestRate
0.10
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
106000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
123000
us-gaap Operating Lease Cost
OperatingLeaseCost
229000
us-gaap Operating Lease Cost
OperatingLeaseCost
246000
CY2020Q2 us-gaap Lease Cost
LeaseCost
106000
CY2019Q2 us-gaap Lease Cost
LeaseCost
123000
us-gaap Lease Cost
LeaseCost
229000
us-gaap Lease Cost
LeaseCost
246000
us-gaap Operating Lease Payments
OperatingLeasePayments
227000
us-gaap Operating Lease Payments
OperatingLeasePayments
237000
CY2019Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8369000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9015000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
88000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
859000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
367000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1757000
CY2020Q2 eyes Number Of Retained Employees
NumberOfRetainedEmployees
10
CY2020Q2 us-gaap Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net
ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
3000000

Files In Submission

Name View Source Status
0001564590-20-040021-index-headers.html Edgar Link pending
0001564590-20-040021-index.html Edgar Link pending
0001564590-20-040021.txt Edgar Link pending
0001564590-20-040021-xbrl.zip Edgar Link pending
eyes-10q_20200630.htm Edgar Link pending
eyes-20200630.xml Edgar Link completed
eyes-20200630.xsd Edgar Link pending
eyes-20200630_cal.xml Edgar Link unprocessable
eyes-20200630_def.xml Edgar Link unprocessable
eyes-20200630_lab.xml Edgar Link unprocessable
eyes-20200630_pre.xml Edgar Link unprocessable
eyes-ex311_8.htm Edgar Link pending
eyes-ex312_7.htm Edgar Link pending
eyes-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending